Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Apr 29, 2022 4:38pm
144 Views
Post# 34643689

RE:RE:Seller balance

RE:RE:Seller balanceCorrect - the seller is done.  I posted it yesterday, based on my assumption of 30-50% of vol and not including the 112k share cross. I've also noticed the 100-200 share every 15-20 minute trade regardless of price (which is a typical algo put in place) stopped over the last 2 days. My guestimate is they are gone. My warning yesterday was that, like any trading analysis, there could be others so take it with a grain of salt.  

My hope is that this will work in the reverse if there is positive newsflow around the finish of 1a and the beginning of 1b.  There are two data points we could hear updates -- next weeks conference presentation and the annual meeting.  All we know at this point is that the first 3 at 300 had either completed their cycle or were close, and they had no SAEs and that they were close to getting the final 3.  It would be crucial to know there were no safety issues and that that dose stands --on to the basket where the tumors should show a higher degree of overexpressed sortilin to "common" sortilin, thus getting loads of chemo into the tumor relative to all the other places sortilin will "latch-on" to the PDC.  




palinc2000 wrote: Looks like the end of the selling is close


Wino115 wrote: Same pattern last 2 days. One interesting little pattern yesterday was that when they leave the market, the share rises.  They let it rise and then his every single bid down .10-.12 cents to unload a larger chunk.  My guestimate is they will only have around 20-30k left after today, so they will likely be out in no more than 2-3 days. Now, for all I know someone else has joined in with that algo selling, but we'll find out next week probably. 




<< Previous
Bullboard Posts
Next >>